Business Context and Reporting Period
This summary covers the Form 10-Q filed by Schering-Plough Corporation for the quarterly period ended June 30, 2008. The company operates in three segments: Human Prescription Pharmaceuticals, Animal Health, and Consumer Health Care. The reporting period is significantly influenced by the integration of the Organon BioSciences N.V. (OBS) acquisition, which closed in November 2007 for approximately $16.1 billion. The company is also navigating challenges related to the Merck/Schering-Plough cholesterol joint venture (VYTORIN and ZETIA) following the release of the ENHANCE clinical trial results.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2008 | Six Months Ended June 30, 2008 |
|---|---|---|
| Net Sales | $4,921 million | $9,577 million |
| Net Income | $436 million | $726 million |
| Net Income Available to Common Shareholders | $398 million | $651 million |
| Diluted Earnings Per Share (EPS) | $0.24 | $0.40 |
| Gross Margin | 61.2% | 57.8% |
| Operating Cash Flow | N/A | $1,384 million |
| Cash and Cash Equivalents (End of Period) | $2,705 million | $2,705 million |
| Total Debt | $9.5 billion | $9.5 billion |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 55% ($1.7 billion) for the quarter and 56% ($3.4 billion) for the six months compared to the same periods in 2007. This growth is primarily driven by the inclusion of OBS products, which contributed $1.4 billion in sales for the quarter and $2.8 billion for the six months.
- Profitability Decline: Despite revenue growth, Net Income available to common shareholders decreased 23% for the quarter ($398 million vs. $517 million) and 39% for the six months ($651 million vs. $1,060 million). This decline is attributed to significant non-cash purchase accounting charges related to the OBS acquisition (amortization of inventory and intangibles) and increased R&D and SG&A expenses.
- Margin Compression: Gross margin decreased to 61.2% (Q2) and 57.8% (YTD) from 69.3% and 68.9% in the prior year, respectively. Purchase accounting items unfavorably impacted gross margin by $354 million in Q2 and $1.0 billion YTD.
- Cholesterol Joint Venture: Global combined sales of VYTORIN and ZETIA decreased 2% YTD, with a 16% decline in the U.S. market due to the ENHANCE trial results. However, equity income from the joint venture increased slightly due to a $64 million gain from the termination of a separate respiratory joint venture.
Outlook, Risks, and Management Commentary
- Productivity Transformation Program (PTP): Announced in April 2008, this program targets $1.5 billion in annualized savings by 2012 to offset integration costs and industry headwinds. Approximately 1,100 positions were eliminated through June 30, 2008.
- Cholesterol Franchise Outlook: Management anticipates U.S. sales of VYTORIN and ZETIA will decline year-over-year in the second half of 2008. Consequently, equity income is expected to be lower in the second half of 2008 than in the first half.
- R&D Spending: R&D spending is expected to be higher in the second half of 2008 as the company advances late-stage pipeline compounds.
- Legal and Regulatory Risks:
- ENHANCE/SEAS Trials: Ongoing investigations by Congress, state Attorneys General, and the DOJ regarding the timing of ENHANCE trial disclosures and stock sales by executives. Multiple class-action lawsuits are pending.
- SEAS Trial Results: Released July 21, 2008, showing no significant difference in primary endpoints for aortic stenosis but an unexpected imbalance in cancer incidence (later analyzed by Oxford CTSU as likely an anomaly).
- Manufacturing: Continued scrutiny of manufacturing practices and pharmacovigilance systems.
- Liquidity: The company maintains a $2.0 billion credit facility and significant cash reserves. Net debt was approximately $6.7 billion as of June 30, 2008.
Key Facts for Investor Verification
- OBS Integration Impact: Verify the sustainability of revenue growth once the one-time purchase accounting amortization charges (approx. $1.1 billion in inventory step-up) are fully recognized.
- Cholesterol Joint Venture Trajectory: Monitor the trend of U.S. sales for VYTORIN and ZETIA, which are critical to the company's profitability but currently facing significant headwinds.
- Legal Exposure: Assess the potential financial impact of pending litigation and government investigations related to the ENHANCE trial and the Massachusetts Investigation settlement.
- Cost Savings Execution: Track the progress of the Productivity Transformation Program (PTP) in achieving the targeted $1.5 billion in annualized savings.
- Debt Structure: Note the company's reliance on Euro-denominated debt and the associated foreign exchange risks, as well as the recent $310 million principal repayment on a Euro term loan.